SCHEMBL2023917

SCHEMBL2023917

CCCCCCCCCCCC(C(=O)O)P(=O)(O)O

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FDPS P14324 4/20 0.59
LAP3 P28838 2/20 0.55
GPR84 Q9NQS5 3/20 0.53
FOLH1 Q04609 1/20 0.53
FFAR1 O14842 1/20 0.53
MAPT P10636 1/20 0.52
LCK P06239 1/20 0.52
PPARD Q03181 1/20 0.52
ZDHHC20 Q5W0Z9 1/20 0.52
ZDHHC2 Q9UIJ5 1/20 0.52
S1PR2 O95136 5/20 0.50
S1PR1 P21453 5/20 0.50
S1PR3 Q99500 5/20 0.50
S1PR4 O95977 4/20 0.50
SMPD1 P17405 2/20 0.48
ACE2 Q9BYF1 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3470937 1.00 FDPS (0.59) FDPSLAP3GPR84FOLH1FFAR1
SCHEMBL3472188 1.00 FDPS (0.59) FDPSLAP3GPR84FOLH1FFAR1
SCHEMBL2339158 1.00 FDPS (0.59) FDPSLAP3GPR84FOLH1FFAR1
SCHEMBL5575815 1.00 FDPS (0.59) FDPSLAP3GPR84FOLH1FFAR1
SCHEMBL9487038 1.00 FDPS (0.59) FDPSLAP3GPR84FOLH1FFAR1
SCHEMBL9841018 1.00 FDPS (0.59) FDPSLAP3GPR84FOLH1FFAR1
SCHEMBL30595172 1.00 FDPS (0.59) FDPSLAP3GPR84FOLH1FFAR1
SCHEMBL3377184 1.00 FDPS (0.59) FDPSLAP3GPR84FOLH1FFAR1
Butane SCHEMBL2906335 0.98 FDPS (0.57) FDPSLAP3GPR84FOLH1FFAR1
SCHEMBL389804 0.98 FDPS (0.57) FDPSLAP3GPR84FOLH1FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2338537-A2 Aptamer coated implant, process of production and uses Biotronik VI Patent AG (CH) 2011-06-29 EP disclosed
US-20110150964-A1 APTAMER-COATED IMPLANT, PROCESS OF PRODUCTION, AND USES BIOTRONIK VI PATENT AG (CH) 2011-06-23 US disclosed
EP-1952831-B1 Stent covered with biomolecules and method for its production BIOTRONIK VI PATENT AG (CH) 2010-05-12 EP disclosed
US-20080215140-A1 STENTS COATED WITH BIOMOLECULES AND PROCESS FOR THEIR PRODUCTION BIOTRONIK VI PATENT AG (CH) 2008-09-04 US disclosed
EP-1952831-A1 Stent covered with biomolecules and method for its production BIOTRONIK VI Patent AG (CH) 2008-08-06 EP disclosed
US-5260051-A Surfactants, soaps, toothpastes LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) 1993-11-09 US disclosed
EP-0493927-A1 Phosphate esters and compositions containing them UNILEVER PLC (GB) 1992-07-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110150964-A1 APTAMER-COATED IMPLANT, PROCESS OF PRODUCTION, AND USES ITGAV, ITGB3, ITGA5 FDPS 2760/4885LAP3 2503/4885GPR84 565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.